Theratechnologies Patent-Cliff Exposure & CMS Drug Spending Portfolio

Theratechnologies (US): 2 reconciled FDA prescription therapies, $16.5M 2024 CMS Part D & Medicaid spend, and $7,656 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$16.5M
2024 Medicare Part D Spend$12.4M
2024 Medicaid Spend$4.1M
California HCAI SB 17 FilingsSpecialty launch notice ($7,656 intro WAC)